Figure 4. AR expression and RFS according to hormone receptor and HER2 status. AR positivity was significantly associated with longer RFS in hormone receptor-positive breast cancer (n = 721) (A) and HER2-negative tumors (n = 806) (B) (both log-rank p < 0.001). In hormone receptor-negative (n = 236) and HER2-positive (n = 151) patients, AR positivity tended to show a longer RFS, but this was not statistically significant (log-rank p = 0.074 and p = 0.205, respectively).

AR = androgen receptor; RFS = relapse-free survival; HER2 = human epidermal growth factor receptor 2.